Calypso(R) Medical Technologies Inc. received FDA clearance for the Calypso 4D Localization System. The system utilizes proprietary electromagnetic technology in conjunction with implanted Beacon(R) transponders in the prostate. The product was designed to provide tumor location information during external beam radiation therapy without adding ionizing radiation.
During radiation therapy, the system can monitor organ motion for cancer patients. With clinicians expected to have greater knowledge of tumor location, it may ensure that the radiation beam is always on target. The product does not require expertise in interpreting X-ray or ultrasound images, so it reduces the time to perform patient setup.


Additional Content

News | Radiation Therapy

Oct. 1, 2026 — At ASTRO 2026 Elekta highlighted new data showing unprecedented long-term survival outcomes for patients ...

Time October 05, 2026
arrow
News | Radiology Imaging

Sept. 22, 2026 — Clinicians’ hands can receive up to 1,000 times more radiation than other parts of the body during ...

Time September 22, 2026
arrow
News | Interventional Radiology

June 29, 2026 – GE HealthCare has introduced Allia platform upgrade pathways designed to help customers modernize select ...

Time July 01, 2026
arrow
News | Interventional Radiology

Feb.12, 2026 — The University of South Florida’s Center for Advanced Medical Learning and Simulation (CAMLS), part of ...

Time February 23, 2026
arrow
News | Interventional Radiology

Dec. 1, 2025 — GE HealthCare has unveiled the Allia Moveo,1 an image guiding solution designed to enhance mobility and ...

Time December 02, 2025
arrow
Subscribe Now